How do anesthesiologists select patients when introducing a new drug into practice?

Area of Science:

• Anesthesiology
• Pharmacology
• Clinical Research

Background:

• Propofol (Diprivan) received FDA approval in 1989.
• A Phase IV postmarketing study was initiated to evaluate its adoption.
• Stuart Pharmaceuticals sponsored this study as part of its marketing strategy.

Purpose of the Study:

• To test the hypothesis that anesthesiologists' use of propofol evolves over time.
• To determine if initial propofol use was limited to younger, healthier patients.
• To assess if experienced anesthesiologists later used propofol for older, sicker patients.

Main Methods:

• A large-scale, multicenter Phase IV study involving 1722 institutions and 1819 anesthesiologists.
• Data collected voluntarily from 25,981 patients using standardized forms.
• Analysis by an independent team of anesthesiologists and epidemiologists to compare early vs. later patient cohorts within sequential study steps.

Main Results:

• Physicians initially administered propofol to patients with fewer comorbidities than the general population.
• Early propofol recipients had lower rates of hypertension (10% vs. 16%) and diabetes (3% vs. 10%) compared to general population averages.
• The study design involved three sequential steps of increasing propofol utilization for anesthesia induction and maintenance.

Conclusions:

• The study supports the hypothesis that propofol adoption by anesthesiologists follows an experience-based progression.
• Initial use was concentrated in lower-risk patient groups.
• Further analysis would be needed to confirm the shift to higher-risk patients over time.